Dr. Patrick Colosimo, Co-Founder, Chairman and CEO of Factor, said, “This is the fifth year that Factor will present our latest data at the Annual Meeting of the ASGCT. This year promises to be particularly exciting, as we present our progress on deploying the powerful mRNA cell-engineering technologies that we have built at Factor over the last decade.” Dr. Kamel Fahmy, Director of Translational Science at Factor, commented, “We have been working hard over the last year to address several critical needs in our industry, including tissue-targeted delivery of nucleic acids, durable allogeneic cell therapies, and effective approaches for targeting solid tumors. We look forward to presenting our results in these and other areas next month at the ASGCT Annual Meeting.” Details of the presentations are available on the ASGCT website. Founded in 2011, Factor Bioscience develops technologies for engineering cells to promote health and improve lives. The company is privately held and headquartered in. For more information, please visit the Factor Bioscience website.
Factor Bioscience to Showcase mRNA and Cell-Engineering Technologies at ASGCT Annual Meeting
